Please login to the form below

Not currently logged in
Email:
Password:

BARDA to support GSK's antibiotic research

GSK and BARDA have agreed a contract supporting GSK's development of a potential novel antibiotic against hospital Gram negative and biothreat pathogens

GlaxoSmithKline (GSK) and the Biomedical Advanced Research and Development Authority (BARDA) have agreed a contract which will support GSK's development of a potential novel antibiotic against hospital Gram negative and biothreat pathogens.

Initially, GSK will receive a $38.5m award from BARDA, a division in the US Department of Health and Human Services, over two years. This award will not only contribute to existing studies, but also new research into various biothreat pathogens; such as Yersinia pestis, the cause of bubonic plague, and Bacillus anthracis, the cause of anthrax.

Specifically, the award will be used to contribute to the development of GSK2251052, an experimental antibiotic, against the bacterial enzyme leucyl tRNA synthetase.

GSK welcomed the agreement with BARDA, which acts as part of BARDA's effort to support the "advanced development of countermeasures that address emerging disease threats and public health".

If BARDA follows the options for future funding, it may bring the total value of the award to $94.5m.

7th September 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CDM London

Brands, categories, relationships, and careers at CDM London - we want to grow them all....

Latest intelligence

UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...
Online Physician Communities
How can pharma innovate in child and TYA cancer?
by Dr Tim Ringrose, M3 (EU)...